Clinical portfolio strategy for regenerative muscle stem cell therapies

Objetivo

MyoPax is a women founded company with locations in Germany and in Denmark. Myopax uses a proprietary, patented, first-in-class stem cell technology to become the leading engineering platform for the treatment of skeletal muscle wasting disorders. In Europe alone, more than 20M people are affected by the devastating consequences of muscle wasting. Only palliative care is available.

We developed a method to produce pure and highly regenerative muscle stem cell populations (PHSats, Primary Human Satellite cell-derived stem cells). Preclinically, PHSats potently build new muscle and refill the muscle stem cell pool (long-term effect). We are setting up three stem cell platforms for today’s unmet medical needs: 1. Satori: Original PhSats (patented in EU/2021, US/2022) to treat local muscle defects with a single injection. 2. Satgeno: Genetically corrected PHSats in genetic muscular dystrophies. A patent has been filed in 2022. Satori and Satgeno are clinical-trial-ready. First-patient-in is planned for Q3 2023. 3. Satuni: Muscle stem cells derived from induced pluripotent stem cell (iPSC) as a universal allogenic muscle stem cell product. We will deliver preclinical efficacy in 2024 for thus off-the-shelf product.

With Women TechEU, we aim to further develop our clinical strategy including an international regulatory and IP strategy, detailed market analysis, and network building with KOL. The mentoring will help us to prepare the fundraising round, which includes company valuation strategies, preparation for due diligence and financial planning. The support will get MyoPax venture capital ready to leverage the technological potential and expand the clinical portfolio- giving back muscle power to those who need it.